CA-ROOTSTOCK-SOFTWARE
30.6.2020 07:02:07 CEST | Business Wire | Press release
Some partnerships are strengthened through difficult times. Rootstock Software and Mobidiag Ltd . found themselves in just this situation. Collaborating since 2018, the two companies have now been working toward respective missions around the COVID-19 pandemic. Mobidiag is a manufacturer of molecular diagnostic solutions for the detection of infectious diseases. Rootstock is a leading provider of Cloud ERP on the Salesforce Platform .
When the pandemic hit, Mobidiag quickly mobilized to develop and launch tests to detect COVID-19 infections. In April 2020, it was granted emergency use authorization for its COVID-19 diagnostic tests in Finland, Sweden and France. Now, in June, it has received CE-IVD markings for its two tests that enable rapid and reliable detection of COVID-19 infections:
- Novodiag™ COVID-19 for single, on-demand tests.
- Amplidiag™ COVID-19 for batch volume tests at large laboratories.
These two tests are complemented by an antibody test, Anti-SARS-CoV-2 Rapid Test , which Mobidiag distributes from its venture partner in China, Autobio Diagnostics.
All together these tests mean Mobidiag offers a comprehensive diagnostic solution for novel coronavirus infections for hospital and lab-based settings, and it comes at an opportune time, as the demand for COVID-19 diagnostic devices and tests is high around the world.
“Since April 2018, we have used Rootstock ERP along with Salesforce Sales Cloud and Service Cloud,” said Harri Vaihinen, Senior Business Solution Specialist at Mobidiag . “We worked with Rootstock to enable greater integration and automation of our key processes across sales, inventory and service for greater efficiency, synchronization and a full view of data across these departments. Since we had this ERP and integrated processes in place, we were able to use these tools to support our rapidly increasing sales, including COVID-19 tests.”
“During the pandemic, Rootstock’s mission has been to support manufacturers, distributors and supply chain organizations in continuing to deliver vital products around the world,” said Pat Garrehy , CEO of Rootstock Software . “It’s impressive to have seen the strides Mobidiag has made to get their COVID-19 tests to market in such an accelerated timeframe. The world needs COVID-19 testing, and it’s gratifying to play even a small role in supporting Mobidiag in their objective to detect COVID-19 infections and slow the spread of the virus.”
Salesforce, Sales Cloud and others are among the trademarks of salesforce.com, inc.
About Mobidiag
Mobidiag is a commercial stage, fast growing molecular diagnostics company whose fast, cost-effective, widely applicable and robust technology makes the power of molecular diagnostics available to address the spread of infectious diseases and antimicrobial resistance by rapid detection of pathogens and their potential resistance to antibiotics. Through its Amplidiag™ and Novodiag™ solutions, Mobidiag offers a comprehensive range of molecular diagnostic solutions for the detection of infectious diseases to laboratories of all sizes.
About Rootstock
Rootstock Software is a worldwide provider of cloud ERP designed for manufacturing, distribution, and supply chain organizations. Rootstock Cloud ERP is a flexible, modern, and digitally connected system that transforms companies to deliver a more personalized customer experience, efficiently scale operations, and out-service the competition.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200629005024/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incentive Market Set to Surpass $80B by 2030s — IMA Launches Tools to Help the Industry Keep Pace4.5.2026 16:28:00 CEST | Press release
With combined business spend on loyalty, employee recognition, and channel incentives projected to exceed $80 billion by the 2030s, the incentive industry is entering a period of rapid scale and strategic pressure. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260422729016/en/ In response, the Incentive Marketing Association (IMA) launched a new suite of resources designed to help incentive professionals navigate an environment that’s becoming more specialized, fragmented, and central to business performance. “It’s not just more money coming in—it’s more complexity,” said Vince Chiofolo, President of the Incentive & Engagement Solution Providers (IESP). “Buyers are demanding programs that evolve fast, integrate deeply, and feel personal at scale. These new tools were built for that.” IMA’s Suite of Tools Includes: New Industry Report — Inside the Incentive Buyer’s Mind Drawn from insights of 50+ program owners, the report f
Tigo Energy Breaks Global Growth Benchmark; Boosts U.S. Energy Feature in Predict+4.5.2026 15:00:00 CEST | Press release
Advanced energy prediction platform adds real-time energy pricing for North American Independent System Operator (ISO) customers, accelerates meters-connected growth. Tigo Energy, Inc. (NASDAQ: TYGO) (“Tigo” or “Company”), a leading provider of intelligent solar and energy solutions, today announced that the Predict+ platform now offers integrated real-time spot market pricing for ISO customers in the United States. Predict+ provides utilities with deep insights into grid demand, renewable generation, and energy market dynamics, enhancing the precision, scalability, and robustness of energy forecasting to up to 97.5% accuracy through machine learning and artificial intelligence. For energy providers, Predict+ helps streamline operations, reduce volatility, and maximize performance. Predict+ empowers utility operators to adapt to real-world demand challenges when balancing renewable and baseload generation sources, particularly during extreme weather events and market disruptions. On th
Airship Announces 2026 Elevate Customer Experience Award Winners4.5.2026 15:00:00 CEST | Press release
Southwest Airlines, The Economist, and OneFootball among brands recognized at Elevate’26 Customer Experience Summit for setting the standard in mobile-first and AI-centered customer experiences Airship, the mobile-first customer experience company, today announced the winners of the 2026 Elevate Customer Experience Awards. Global brand leaders from The Economist, Southwest Airlines, and OneFootball were among those honored at the Elevate’26 Customer Experience Summit. The Elevate Awards spotlight global companies that have developed exceptional mobile-first customer experiences for their customers, created innovative campaigns, leveraged AI agents to reach new levels of productivity, and achieved real business results. "Evolving mobile-first consumer behaviors and unprecedented advancements in AI are driving a seismic shift that is reshaping how brands interact with their customers," said Brett Caine, CEO, Airship. "The 2026 Elevate Award winners aren’t just adapting, they’re leading t
Alnylam to Present New Analyses at Heart Failure 2026 Underscoring Consistent Clinical Profile of Vutrisiran in ATTR-CM4.5.2026 14:30:00 CEST | Press release
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced it will present new data analyses for vutrisiran in patients with the cardiomyopathy of wild-type or hereditary transthyretin-mediated amyloidosis (ATTR-CM) at Heart Failure 2026, a scientific congress of the European Society of Cardiology, taking place May 9-12, 2026, in Barcelona, Spain. ATTR-CM is a heterogeneous and rapidly progressive disease, and patients often present with complex clinical profiles. At Heart Failure 2026, Alnylam will present multiple new analyses from the Phase 3 HELIOS-B study of vutrisiran, which continue to support its use as a first-line treatment for patients with ATTR-CM, and further characterize its clinical profile across patients with a high disease burden, and in the context of concomitant therapies. Vutrisiran is the first and only transthyretin (TTR) silencer for ATTR-CM that delivers rapid knockdown of TTR at the source. Additional analyses being pr
Takeda Announces Positive Topline Results from Pivotal Phase 2/3 Clinical Trial of TAK-881 in Primary Immunodeficiency Disease (PID)4.5.2026 14:00:00 CEST | Press release
Investigational TAK-881 was comparable to established HYQVIA while also demonstrating reduced infusion volume and duration for PID patients Takeda (TSE:4502/NYSE:TAK) today announced that TAK-881-3001, a pivotal Phase 2/3 clinical trial in patients with Primary Immunodeficiency Disease (PID), met its primary endpoint, which demonstrated pharmacokinetic (PK) comparability between the investigational TAK-881 [Immune Globulin Subcutaneous (Human), 20% Solution (SCIG 20%) with Recombinant Human Hyaluronidase] and HYQVIA [Immune Globulin Infusion (Human) 10% with Recombinant Human Hyaluronidase]. Additionally, secondary endpoints showed that TAK-881, a SCIG 20% facilitated with hyaluronidase, demonstrated safety, efficacy and tolerability profiles comparable to HYQVIA, an established SCIG 10% facilitated with hyaluronidase. These findings support the potential of TAK-881 to deliver the required immunoglobulin (IG) dose for PID patients in half the volume of HYQVIA, reducing infusion duratio
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom